Pharmaceutical company Bristol-Myers Squibb Co. has partnered with the University of California - Los Angeles' (UCLA) David Geffen School of Medicine for Bristol-Myers Squibb's national Immuno-Oncology Rare Population Malignancy (I-O RPM) research program.
I-O RPM is a research and treatment method wherein the body's immune system fights cancer. The method is used for rare population malignancies -- a sub-group of cancers within a broader range. The prognosis for patients stricken with these cancers is often very poor; the diseases are very aggressive and tend to spread quickly and recur.
Scientists from both organizations will conduct research. Funding will be provided by Bristol-Myers Squibb.
Research for the program will be conducted at academically based cancer centers. Researchers will focus early-phase clinical studies on possible treatments for cancer patients with cancers that carry a high mortality rate.
“The I-O RPM research program is an important complement to Bristol-Myers Squibb’s broad research and development program for immuno-oncology,” Dr. Laura Bessen, head of U.S. medical for Bristol-Myers Squibb, said. “We look forward to working with UCLA in an effort to continue advancing the science in this innovative field of research and cancer treatment.”
For more information, visit www.bms.com or the Bristol-Myers Squibb Twitter page.
